See More Hear More Watch More Hear More Get on iTunes
Marketplace marketplace

People affected by rare diseases in U.S.

Alexion Pharmaceuticals announced this week it is buying Synageva Biopharma for $8.4 billion. Alexion develops so-called orphan drugs, treatments for rare diseases. In the U.S., rare diseases, most of them genetic, affect about 30 million people. #FullNewsAudioAvailable


More from